RE:RE:CXR vs ITNot bad Lattice but it's clear you are a short seller here trying to find reasons not to cover at the lows.
As for the "analysts", you can bet some were also short and want to portrait the company as poorly as they can.
This is a sector and country wide attack by our friends in the US and on BayStreet. That's a given.
What is a bit harder is why the best entry point is. The short bashing crew leader here apparently popped up with a new alias tell us they were planning mid $20s CDN, let's see if the clown show can drive it down to that.
One thing for sure, this board as a lot of bulls wanting to defend Concordia.
I'll pull up a chair and popcorn (and charts of course) but I'll try to be quiet to enjoy the show.
Try is the word of the day LOL ;-)
Lattice wrote: fdfd. I agree with you on the US thesis. Is it the anti-Canadian sector condition or the US algo trading robots? However, I diagree on your statement that the shorts have false rumours with CXR. The market is clearly not trusting companies that show "Adjusted earnings." "Adjusted EPS" ..... Buying companies and showing losses in the form of "Costs" is troublesome for some. You can see in companies such as Patient Home Monitoring, Nobilis Health, and Valeant that you can Adjust numbers to be whatever you want them to be to fool only some. It is not a rumor that many Bay Street analysts are now not regarding Mark Thompson as they did before, as he is coming across as being a bit of a high roller with a lot of swagger. The conference call was viewed as a collossal fail and management was viewed as unprepared and their transparancy is now an issue. Some recent information (such as Fx headwinds that management has not considered and Brexit which would put EU trade agreements at jepardy) have put 2016 guidance at risk. Revenues from the Covis portfolio are lower than what analysts expected and certainly lower than Q3. A generic that came on board has threated Dibenzyline, the largest drug in the Covis portfolio and Divesture of Covis injectables (Fortaz, Santac and Zinacef) have led to a N.American revenue decline of 20% in Q4. The biggest slam against the company is the debt levels and they have some pretty large debt payments coming up including the earn out payment. VRX concditions will continue to weigh on the stock price. When people realize that Ackman was in the dark, it speaks volumes to how little they may know and understand the speicalty pharma industry. I know that you are a stront TA Analyst but there are things going on with this company since the short interest began building in October 2015. The market has been betting on the deterioration of this company for quite some time and although I haven't looked at IT, I believe that CXR will have to base for quite some time before the algos will let it move up. And I don't believe that the programs will ever let CXR move up higher than VRX. Thank you fdfd for being honest on this board.
fdfd12 wrote:
both stocks were attacked by false rumours.
Both stocks said, the rumours are unfounded.
IT went up after their denial but not CXR.
CXR went even more down yesterday.
WHY?
answer below
Because CXR trades also in US but not Interain